BLACK DIAMOND THERAPEUTICS INC (BDTX) — insider trading
Health Care · NASDAQ
BLACK DIAMOND THERAPEUTICS INC (BDTX) has 12 reported SEC Form 4 insider transactions in our data (latest 2026-06-26).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-26 | Campbell Shannon | Director | Grant / award / vesting (derivative) | 40,000 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Dhingra Kapil | Director | Grant / award / vesting (derivative) | 40,000 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Raman Prakash | Director | Grant / award / vesting (derivative) | 40,000 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Menzel Garry E | Director | Grant / award / vesting (derivative) | 40,000 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Kulkarni Samarth | Director | Grant / award / vesting (derivative) | 40,000 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Behbahani Ali | Director | Grant / award / vesting (derivative) | 40,000 | $0.00 | $0 | Form 4 |
| 2026-06-19 | Raman Prakash | Director | Grant / award / vesting | 7,907 | $1.66 | $13.1K | Form 4 |
| 2026-06-19 | Behbahani Ali | Director | Grant / award / vesting | 8,961 | $1.66 | $14.9K | Form 4 |
| 2026-03-20 | Raman Prakash | Director | Grant / award / vesting | 6,105 | $2.15 | $13.1K | Form 4 |
| 2026-03-20 | Behbahani Ali | Director | Grant / award / vesting | 6,919 | $2.15 | $14.9K | Form 4 |
| 2026-01-21 | Hatzis-Schoch Brent | Officer (SEE REMARKS) | Grant / award / vesting (derivative) | 250,000 | $0.00 | $0 | Form 4 |
| 2026-01-21 | Jones Erika | Officer (SEE REMARKS) | Grant / award / vesting (derivative) | 200,000 | $0.00 | $0 | Form 4 |
Ask the chat about BDTX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: BLACK DIAMOND THERAPEUTICS INC (BDTX).
Last updated 2026-06-26 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.